Myeloma
Association applauds VELCADE approval
Published in Medical Letter on the CDC and FDA, May 1st, 2005
This approval expands the label to include the treatment of multiple myeloma patients who have received at least one prior therapy.
The approval was based on data from the randomized, phase III APEX study that compared single-agent VELCADE to high-dose dexamethasone. The study demonstrated a pronounced survival advantage in the second-line myeloma patients.
"We are very pleased that we now have a new standard of care in second-line treatment for multiple myeloma which has a statistically significant survival advantage,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Antibiotics
Education increases approval of appropriate antibiotic prescription - Flavivirus
Topology in flavivirus stem-loop determines RNA replication competence - HIV/AIDS Transmission
Condom use and perceived risk of HIV transmission investigated - Influenza Virus
Rapid strategy to characterize influenza B reassortants developed - Pacemakers
Security system simulator to test pacemaker compatibility developed - Adenovirus
Five new adenovirus type 37 strains caused epidemic keratoconjunctivitis - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
